# KPV: Research Overview — Research Peptides US > KPV: research overview covering mechanism, gut-inflammation animal studies, PepT1-targeted delivery research, and why zero published human trials exist. No dosing, no sales, no advice. A three-amino-acid anti-inflammatory fragment of alpha-MSH, studied only in cells and mice — with zero published human trials to date. ## The short version KPV is a tiny peptide — just three amino acids (lysine, proline, valine) linked together — that corresponds to the tail end of a natural hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). The parent hormone does several things in the body, including affecting skin pigment. KPV keeps the anti-inflammatory piece of that activity but drops the pigment-affecting piece, which is why researchers have studied it specifically for calming gut inflammation. Here's the flat truth: KPV has never been tested in a published human clinical trial. Every finding on this page comes from mouse models of colitis or from human cells studied in a dish, not from a person taking it. That's a meaningfully thinner evidence base than the other four compounds on this desk. Researchers describe it as a promising anti-inflammatory lead with a delivery problem — it breaks down fast in the body — and most of the current published work is about engineering better ways to deliver it to inflamed tissue, not about proving it works in people. ## What it is KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to residues 11-13 — the tail end — of alpha-MSH. Molecular formula C16H30N4O4. Because it's such a small fragment, it lacks the pigment-cell-stimulating (melanogenic) activity of the full alpha-MSH hormone while, in preclinical models, retaining its anti-inflammatory signaling. Most current research effort isn't about proving KPV works — animal models already show anti-inflammatory activity — it's about keeping the peptide intact long enough to reach inflamed tissue before it's broken down, since free KPV is a small, enzyme-vulnerable molecule with no established human pharmacokinetics. ## How it works In research models, KPV dampens inflammation primarily by suppressing two major inflammatory signaling pathways — NF-kB and MAP-kinase — and reducing the cells' output of pro-inflammatory cytokines like IL-1beta and TNF-alpha. In the gut specifically, KPV doesn't need a dedicated hormone receptor to get into cells: it's small enough to be taken up directly by intestinal epithelial cells through the di/tripeptide transporter PepT1 (gene SLC15A1), a transporter that is upregulated in inflamed intestinal tissue — meaning KPV may concentrate exactly where inflammation is worst [8]. That PepT1 route is also why recent work focuses on nanoparticle and hydrogel delivery systems: targeting the same transporter that already favors inflamed tissue, to get more intact KPV where it's needed before enzymes break it down [6][7]. ## What the research shows *Nanodrug delivery in colitis.* A 2024 study built a PepT1-targeted nanodrug co-assembling KPV with the immunosuppressant FK506. In mice with both acute and chronic DSS-induced colitis, the combination improved disease outcomes beyond either agent alone, restoring tight-junction proteins (which seal the gut lining) and lowering inflammatory cytokines [6]. *Oral nanoparticle delivery.* Orally administered hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue in mice and reduced colitis severity more effectively than non-targeted formulations — preventing mucosal damage and lowering TNF-alpha more than plain KPV [7]. *The PepT1 transport mechanism.* Foundational work established that KPV is transported into intestinal epithelial cells via PepT1, and that nanomolar concentrations of KPV inhibit NF-kB and MAP-kinase inflammatory signaling and reduce pro-inflammatory cytokine secretion — tested in human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells in vitro, and in DSS- and TNBS-induced colitis in mice, where oral KPV reduced disease severity [8]. *Colitis models, independent of pigment receptor.* KPV reduced colonic inflammation in mice across two colitis models, producing earlier recovery, lower tissue-damage enzyme activity, and reduced inflammatory infiltrate. Critically, the effect was retained in mice lacking the MC1R pigment receptor, confirming the anti-inflammatory action doesn't require the pigmentary pathway [9]. *The broader review.* A comprehensive review of alpha-MSH-derived tripeptides, including KPV, describes broad anti-inflammatory activity — NF-kB suppression, reduced cytokine output — across models of fever, dermatitis, vasculitis, fibrosis, eye disease, gut disease, brain injury, airway disease, and arthritis, while confirming KPV specifically lacks the parent hormone's pigment-related action [10]. ## Reported effects, cautions & safety There is no anecdotal community-reported effects section for KPV on this page, and that absence is itself the finding: KPV has no history of human use to draw self-reports from. Unlike the other four compounds on this desk, there is no meaningful body of forum posts or patient-experience write-ups describing what KPV does in a person, because — as far as the published record shows — essentially no one has taken it outside a laboratory setting. *Cited cautions, drawn from the state of the evidence itself:* no published human clinical trial of KPV exists; the entire efficacy literature is in vitro cell work and animal colitis models, chiefly in mice [6][7][8][9][10] — so human dosing, efficacy, and safety are simply unestablished, not just under-studied. Free KPV is a small, enzyme-vulnerable tripeptide with no validated human pharmacokinetics; that instability is precisely why the newest papers are about nanoparticle and hydrogel delivery rather than efficacy confirmation [6][7]. Marketing claims for gut health, skin, or general anti-inflammatory use in humans outrun what any of this evidence supports — it is mechanistic and preclinical, not clinical. Because KPV derives from alpha-MSH, it should not be confused with melanocortin agonists marketed for tanning or pigmentation — KPV's entire research interest is the opposite: anti-inflammatory activity without the pigment effect. It is a research chemical only, with no approved drug or dietary-supplement status anywhere, and web sources reporting KPV's citation identifiers should be checked against PubMed directly, since errors are common in secondary aggregators. ## Where it fits in Research Peptide Fundamentals KPV is the evidence floor of this desk — the one compound among the five with no human trial data of any kind. Where [BPC-157](/bpc-157) at least has a two-person human safety pilot, and [NAD+](/nad) has multiple placebo-controlled human dosing trials, KPV's entire case rests on mouse colitis models and human cells in a dish. That doesn't mean the mechanism is wrong; it means the human proof simply doesn't exist yet. See the [comparison page](/compare) for how evidence maturity differs across all five compounds. ![KPV research illustration — abstract anti-inflammatory pathway motif in cool graphite tones](/images/kpv.webp) --- A no-nonsense literature rundown on research peptides — straight evidence, no sales, no dosing advice.